logo
  

Zogenix Shares Down 32% After FDA Refuses To Review Seizure Drug

Shares of Zogenix Inc. (ZGNX) plunged 32% in the extended session Monday after the company said the Food and Drug Administration did not accept a marketing application for one of its drugs.

Zogenix, a pharmaceutical company developing rare disease therapies, said it received a Refusal to File letter from FDA regarding its New Drug Application for Fintepla for the treatment of seizures associated with Dravet syndrome.

The FDA determined that the application was not sufficiently complete to permit a substantive review. FDA cited two reasons for the RTF decision: first, certain non-clinical studies were not submitted to allow assessment of the chronic administration of fenfluramine; and, second, the application contained an incorrect version of a clinical dataset, which prevented the completion of the review process that is necessary to support the filing of the NDA.

"We remain highly confident in FINTEPLA's clinical profile demonstrated in the Phase 3 program in Dravet syndrome and are committed to advancing the product candidate as a potential new treatment option for this and other rare and often catastrophic epileptic encephalopathies," said Stephen J. Farr, Ph.D., President and CEO of Zogenix. "We are fully committed to working with the FDA as quickly as possible to address the open issues and clarify the path to successfully re-filing our application."

ZGNX closed Monday's trading at $51.85, down $0.15 or 0.29% on the Nasdaq. The stock further dropped $16.59 or 32% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Omaha, Nebraska- based Greater Omaha Packing is recalling around 295,236 pounds of raw beef products citing the possible presence of E. coli O157:H7, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The raw beef products intended for non-intact use were produced on July 13. Consumer goods giant Procter & Gamble Co. (PG) on Friday reported a four percent increase in profit for the fourth quarter from last year, driven by net sales growth across its operating segments, partially offset by a reduction in operating margin. Both revenue and core earnings per share for the quarter beat analysts' estimates. Looking ahead, the company also initiated outlook for fiscal 2022. While reporting financial results for the second quarter on Friday, Colgate-Palmolive Co. (CL) maintained its earnings, adjusted earnings and sales growth guidance for the full-year 2021. For fiscal 2021, the company now expects earnings per share to grow at the lower end of its low to mid-single-digit...
Follow RTT